Analyst ratings and price targets can significantly influence investor sentiment and stock prices. RBC Capital's reiteration of an Outperform rating and maintenance of a $270 price target for Alnylam Pharmaceuticals indicates a positive outlook for the company, which could lead to an increase in its stock price.